Why Rotarex is my first choice treatment in patients with bypass failure and CLTI: Bruno Migliara

NOTE: This video is ONLY available to watch in selected countries and geographies

Bruno Migliara (Peschiera del Garda, Italy) talks to Vascular News about the reasons why bypass failure, which he notes is “really dangerous for life and limb”, is so complex to treat, particularly in patients with chronic limb-threatening ischaemia (CLTI). There is a “lack of literature” evaluating the clinical outcomes in this specific patient population, he notes.

Migliara discusses what treatment options are available for CLTI patients and why he chooses Rotarex (BD) when taking an endovascular approach. Local thrombolysis has become an alternative treatment for these types of patients but is “too slow” to restore the flow in the case of a really acute ischaemia and also is “not effective” in cases of subacute or chronic bypass occlusion, he says, adding that “the reason why we have started to use Rotarex S in this type of patient” is because, due to its design, “we are able to obtain very quickly, flow restoration without the use of a lytic agent”.

A recent study, published by Migliara et al in the European Journal of Vascular Medicine (VASA), and which was designed to compare open surgery and mechanical atherothrombectomy devices in patients with acute, subacute and chronic bypass occlusion, found that Rotarex is an “effective device in patients with bypass failure and CLTI”. It is also “less invasive than open surgery, less time consuming and also less expensive, producing a greater health benefit with a longer reocclusion time”, adds Migliara before concluding that “it is our first choice treatment” in these patients.

This video is sponsored by BD.

The post Why Rotarex is my first choice treatment in patients with bypass failure and CLTI: Bruno Migliara appeared first on Vascular News.